Cargando…
Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality. In laboratory studies, metformin was reported to affect the survival of cancer stem cells (CSCs) in breast and pancreatic cancers and glioblastoma....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836781/ https://www.ncbi.nlm.nih.gov/pubmed/24278407 http://dx.doi.org/10.1371/journal.pone.0081264 |
_version_ | 1782292348724576256 |
---|---|
author | Zhang, Yanfei Guan, Meiping Zheng, Zongji Zhang, Qian Gao, Fang Xue, Yaoming |
author_facet | Zhang, Yanfei Guan, Meiping Zheng, Zongji Zhang, Qian Gao, Fang Xue, Yaoming |
author_sort | Zhang, Yanfei |
collection | PubMed |
description | In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality. In laboratory studies, metformin was reported to affect the survival of cancer stem cells (CSCs) in breast and pancreatic cancers and glioblastoma. Although cscs play a critical role in the resistance to 5-fluorouracil (5-FU) chemotherapy in CRC patients, the effect of metformin on cscs in CRC patients and the synergistic effect of metformin in combination with 5-FU on cscs are not reported. In the present study pathological examinations were performed in 86 CRC patients complicated with type 2 DM who had been divided into a metformin group and a non-metformin group. Comparisons regarding pathological type, incidence of metastasis, expression of CD133 and β-catenin were conducted between the two groups. We explored the synergistic effects of metformin in combination with 5-FU on the proliferation, cell cycle, apoptosis and the proportion of CD133+ cscs of SW620 human colorectal cancer cell lines. The results show that metformin treatment had reverse correlations with the proportion of patients with poorly differentiated adenocarcinoma, the proportion of CD133+ cscs in CRC patients with type 2 DM. Metformin enhanced the antiproliferative effects of 5-FU on CD133+ cscs in SW620 cells. These findings provide an important complement to previous study. Inhibition of the proliferation of CD133+ cscs may be a potential mechanism responsible for the association of metformin use with improved CRC outcomes in CRC patients with type 2 diabetes. |
format | Online Article Text |
id | pubmed-3836781 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38367812013-11-25 Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients Zhang, Yanfei Guan, Meiping Zheng, Zongji Zhang, Qian Gao, Fang Xue, Yaoming PLoS One Research Article In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality. In laboratory studies, metformin was reported to affect the survival of cancer stem cells (CSCs) in breast and pancreatic cancers and glioblastoma. Although cscs play a critical role in the resistance to 5-fluorouracil (5-FU) chemotherapy in CRC patients, the effect of metformin on cscs in CRC patients and the synergistic effect of metformin in combination with 5-FU on cscs are not reported. In the present study pathological examinations were performed in 86 CRC patients complicated with type 2 DM who had been divided into a metformin group and a non-metformin group. Comparisons regarding pathological type, incidence of metastasis, expression of CD133 and β-catenin were conducted between the two groups. We explored the synergistic effects of metformin in combination with 5-FU on the proliferation, cell cycle, apoptosis and the proportion of CD133+ cscs of SW620 human colorectal cancer cell lines. The results show that metformin treatment had reverse correlations with the proportion of patients with poorly differentiated adenocarcinoma, the proportion of CD133+ cscs in CRC patients with type 2 DM. Metformin enhanced the antiproliferative effects of 5-FU on CD133+ cscs in SW620 cells. These findings provide an important complement to previous study. Inhibition of the proliferation of CD133+ cscs may be a potential mechanism responsible for the association of metformin use with improved CRC outcomes in CRC patients with type 2 diabetes. Public Library of Science 2013-11-21 /pmc/articles/PMC3836781/ /pubmed/24278407 http://dx.doi.org/10.1371/journal.pone.0081264 Text en © 2013 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhang, Yanfei Guan, Meiping Zheng, Zongji Zhang, Qian Gao, Fang Xue, Yaoming Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients |
title | Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients |
title_full | Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients |
title_fullStr | Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients |
title_full_unstemmed | Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients |
title_short | Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients |
title_sort | effects of metformin on cd133+ colorectal cancer cells in diabetic patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836781/ https://www.ncbi.nlm.nih.gov/pubmed/24278407 http://dx.doi.org/10.1371/journal.pone.0081264 |
work_keys_str_mv | AT zhangyanfei effectsofmetforminoncd133colorectalcancercellsindiabeticpatients AT guanmeiping effectsofmetforminoncd133colorectalcancercellsindiabeticpatients AT zhengzongji effectsofmetforminoncd133colorectalcancercellsindiabeticpatients AT zhangqian effectsofmetforminoncd133colorectalcancercellsindiabeticpatients AT gaofang effectsofmetforminoncd133colorectalcancercellsindiabeticpatients AT xueyaoming effectsofmetforminoncd133colorectalcancercellsindiabeticpatients |